Cargando…

Implications of KRAS mutations in acquired resistance to treatment in NSCLC

RATIONALE: KRAS is the most common and, simultaneously, the most ambiguous oncogene implicated in human cancer. Despite KRAS mutations were identified in Non Small Cell Lung Cancers (NSCLCs) more than 20 years ago, selective and specific inhibitors aimed at directly abrogating KRAS activity are not...

Descripción completa

Detalles Bibliográficos
Autores principales:	Del Re, Marzia, Rofi, Eleonora, Restante, Giuliana, Crucitta, Stefania, Arrigoni, Elena, Fogli, Stefano, Di Maio, Massimo, Petrini, Iacopo, Danesi, Romano
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5814239/ https://www.ncbi.nlm.nih.gov/pubmed/29464099 http://dx.doi.org/10.18632/oncotarget.23553

Ejemplares similares

Concise Review: Chronic Myeloid Leukemia: Stem Cell Niche and Response to Pharmacologic Treatment
por: Arrigoni, Elena, et al.
Publicado: (2018)

PD-L1 mRNA expression in plasma-derived exosomes is associated with response to anti-PD-1 antibodies in melanoma and NSCLC
por: Del Re, Marzia, et al.
Publicado: (2018)

Understanding the Mechanisms of Resistance in EGFR-Positive NSCLC: From Tissue to Liquid Biopsy to Guide Treatment Strategy
por: Del Re, Marzia, et al.
Publicado: (2019)

The amount of activating EGFR mutations in circulating cell-free DNA is a marker to monitor osimertinib response
por: Del Re, Marzia, et al.
Publicado: (2018)

erbB in NSCLC as a molecular target: current evidences and future directions
por: Del Re, Marzia, et al.
Publicado: (2020)

The increase in activating EGFR mutation in plasma is an early biomarker to monitor response to osimertinib: a case report
por: Del Re, Marzia, et al.
Publicado: (2019)

A multiparametric approach to improve the prediction of response to immunotherapy in patients with metastatic NSCLC
por: Del Re, Marzia, et al.
Publicado: (2020)

Patients with NSCLC may display a low ratio of p.T790M vs. activating EGFR mutations in plasma at disease progression: implications for personalised treatment
por: Del Re, Marzia, et al.
Publicado: (2017)

Integrating Liquid Biopsy and Radiomics to Monitor Clonal Heterogeneity of EGFR-Positive Non-Small Cell Lung Cancer
por: Cucchiara, Federico, et al.
Publicado: (2020)

Gemcitabine Plus Nab-Paclitaxel Induces PD-L1 mRNA Expression in Plasma-Derived Microvesicles in Pancreatic Cancer
por: Del Re, Marzia, et al.
Publicado: (2021)

Pharmacogenetic Foundations of Therapeutic Efficacy and Adverse Events of Statins
por: Arrigoni, Elena, et al.
Publicado: (2017)

Early changes in plasma DNA levels of mutant KRAS as a sensitive marker of response to chemotherapy in pancreatic cancer
por: Del Re, Marzia, et al.
Publicado: (2017)

Contribution of KRAS mutations and c.2369C > T (p.T790M) EGFR to acquired resistance to EGFR-TKIs in EGFR mutant NSCLC: a study on circulating tumor DNA
por: Del Re, Marzia, et al.
Publicado: (2016)

Multiple Resistance Mechanisms to Tyrosine Kinase Inhibitors in EGFR Mutated Lung Adenocarcinoma: A Case Report Harboring EGFR Mutations, MET Amplification, and Squamous Cell Transformation
por: Bruno, Rossella, et al.
Publicado: (2021)

Detection of KRAS mutant alleles in circulating cell-free tumor DNA in colorectal cancer patients resistant to cetuximab
por: Del Re, Marzia, et al.
Publicado: (2014)

Nanopore sequencing from liquid biopsy: analysis of copy number variations from cell-free DNA of lung cancer patients
por: Martignano, Filippo, et al.
Publicado: (2021)

Androgen receptor gain in circulating free DNA and splicing variant 7 in exosomes predict clinical outcome in CRPC patients treated with abiraterone and enzalutamide
por: Del Re, M., et al.
Publicado: (2021)

CDK4/6 Inhibitors Overcome Endocrine ESR1 Mutation-Related Resistance in Metastatic Breast Cancer Patients
por: Crucitta, Stefania, et al.
Publicado: (2023)

Concomitant administration of proton pump inhibitors does not significantly affect clinical outcomes in metastatic breast cancer patients treated with ribociclib
por: Del Re, Marzia, et al.
Publicado: (2022)

Amivantamab in the Treatment of Metastatic NSCLC: Patient Selection and Special Considerations
por: Petrini, Iacopo, et al.
Publicado: (2022)

Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients
por: Del Re, M., et al.
Publicado: (2021)

Reply to comments on: Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients
por: Del Re, M., et al.
Publicado: (2022)

The amount of DNA combined with TP53 mutations in liquid biopsy is associated with clinical outcome of renal cancer patients treated with immunotherapy and VEGFR-TKIs
por: Del Re, Marzia, et al.
Publicado: (2022)

KRAS in NSCLC: State of the Art and Future Perspectives
por: Cascetta, Priscilla, et al.
Publicado: (2022)

Evolution of acquired resistance in a ROS1(+) KRAS G12C(+) NSCLC through the MAPK pathway
por: Priest, Katherine, et al.
Publicado: (2023)

Editorial: Primary and acquired resistance in lung cancer
por: Bruno, Rossella, et al.
Publicado: (2023)

Identification of a targetable KRAS-mutant epithelial population in non-small cell lung cancer
por: Maroni, Giorgia, et al.
Publicado: (2021)

Base excision repair-mediated resistance to cisplatin in KRAS(G12C) mutant NSCLC cells
por: Caiola, Elisa, et al.
Publicado: (2015)

Wee1 inhibitor MK1775 sensitizes KRAS mutated NSCLC cells to sorafenib
por: Caiola, Elisa, et al.
Publicado: (2018)

Treating KRAS-mutant NSCLC: latest evidence and clinical consequences
por: Garrido, Pilar, et al.
Publicado: (2017)

A Radiogenomics Ensemble to Predict EGFR and KRAS Mutations in NSCLC
por: Moreno, Silvia, et al.
Publicado: (2021)

The Inherited KRAS-variant as a Biomarker of Cetuximab Response in NSCLC
por: Weidhaas, Joanne B., et al.
Publicado: (2023)

Radiomics and liquid biopsy in oncology: the holons of systems medicine
por: Neri, Emanuele, et al.
Publicado: (2018)

A Real-World Application of Liquid Biopsy in Metastatic Colorectal Cancer: The Poseidon Study
por: Procaccio, Letizia, et al.
Publicado: (2021)

Comparative metabolomics profiling of isogenic KRAS wild type and mutant NSCLC cells in vitro and in vivo
por: Brunelli, Laura, et al.
Publicado: (2016)

Kras mutations increase telomerase activity and targeting telomerase is a promising therapeutic strategy for Kras-mutant NSCLC
por: Liu, Weiran, et al.
Publicado: (2016)

Discovery of novel mutations in the dihydropyrimidine dehydrogenase gene associated with toxicity of fluoropyrimidines and viewpoint on preemptive pharmacogenetic screening in patients
por: Del Re, Marzia, et al.
Publicado: (2015)

BET inhibition is an effective approach against KRAS-driven PDAC and NSCLC
por: Jauset, Toni, et al.
Publicado: (2018)

KRAS G12C Mutations in NSCLC: From Target to Resistance
por: Addeo, Alfredo, et al.
Publicado: (2021)

Adagrasib: A landmark in the KRAS(G12C)‐mutated NSCLC
por: Tian, He, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_p3n27en85q483okgrlgok4uf30